Try our Advanced Search for more refined results

Expert Analysis

Lessons From Red Yeast Rice May Inform FDA's Path For CBD

By Greg Kaufman, Meghana Shah and Amber Unwala (May 28, 2019, 12:57 PM EDT) -- As the cannabis industry grows, all eyes are on the U.S. Food and Drug Administration to define its regulation and enforcement approach to products containing cannabidiol. CBD derived from cannabis plants has been touted for its therapeutic properties.[1] How the FDA will choose to regulate CBD remains uncertain. Will the FDA look at prior precedent involving red yeast rice,[2] an infamous decision in the eye of the dietary supplement industry, and what influence may this precedent have on their decision-making regarding CBD?...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!